Updated:
M Ventures
M Ventures is Merck KGaA's strategic corporate VC, deploying €600M across 100+ biotech and tech investments since 2009 under Managing Director Hakan Goker.
M Ventures
M Ventures is an SEC-registered investment adviser in Los Angeles, CA, registered since 2018. It advises clients from its California office. M Ventures is based in Los Angeles.
General information
Firm type
Venture Capital
Year founded
2009
AUM
Undisclosed
Location
Region
North America
Country
Netherlands
City
Amsterdam
Corporate office
Eduard van Beinumstraat 26, 1077 CZ Amsterdam, Netherlands
Additional offices
Helsinki, Finland · Berlin, Germany · Los Angeles, United States · Stockholm, Sweden
Principals
Hakan Goker
Managing Director
Javier Rodriguez
Head Technology Investments
Caroline Soulard
Chief Financial Officer
Ebru Uzun
Head of Business Operations
Sector focus
Frequently asked questions
Who runs investment decisions at M Ventures?
Managing Director Hakan Goker leads the investment team, with Javier Rodriguez heading Technology Investments. Decisions are made by an executive director group that includes Bauke Anninga, Christian Patze, Christian Uhrich, and Daniel Franke, drawing on expertise across biotechnology, electronics, and frontier technology.
How does M Ventures source proprietary deal flow?
The firm originates deal flow through its embedded relationship with Merck KGaA, identifying spin-offs from internal research (such as Calypso Biotech) and co-developing companies that align with the parent's R&D priorities. It also maintains a network of co-investors and academic institutions across its European, Israeli, and US offices.
Is M Ventures a typical venture capital firm or something else?
M Ventures operates as a strategic corporate venture capital fund. It pursues dual financial and strategic returns — meaning every investment must offer a credible path to commercial return while also complementing Merck KGaA's therapeutic, tool, or technology roadmaps.
Does M Ventures invest only directly or also via co-investment?
The firm participates in direct equity financings and regularly co-invests alongside other venture and growth equity funds. Portfolio company statements indicate M Ventures was instrumental in building syndicates for rounds such as the Series A for LabGenius and later-stage financings for STORM Therapeutics.
What stages does M Ventures typically target?
M Ventures invests across early-stage (seed and startup) and growth stages. It has backed companies from initial conception through to IPO (Translate Bio, Progyny, Galecto Biotech) and M&A exits (Ambrx, Synaffix BV, Calypso Biotech), often holding positions through multiple funding rounds.
How is M Ventures related to Merck KGaA?
M Ventures is the wholly owned corporate venture arm of Merck KGaA, Darmstadt, Germany. It receives its capital allocation from the parent and operates with access to Merck's research scientists, labs, and commercial infrastructure, though it makes independent investment decisions.
Does M Ventures maintain a separate capital structure or raise external funds?
The firm operates on a €600 million allocation from its corporate parent, Merck KGaA. It has not raised external limited partner capital. All portfolio activity is funded through this dedicated corporate venture budget, which supports both new investments and follow-on rounds.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: